CFLAR and prostate cancer: Taken together, these data demonstrate that WA targets vimentin and promotes cell death in prostate cancer cells, but not in normal fibroblasts, through increased c-Fos level, reduced FLIP level, and/or enhanced ROS generation probably via WA-mediated disruption of the cytoskeletal architecture.